<DOC>
	<DOCNO>NCT00511745</DOCNO>
	<brief_summary>The purpose study evaluate safety rabeprazole 20mg/day polymedicated patient examine necessity adjust dosage therapy ( rabeprazole concomitant drug ) . Proton pump inhibitor ( PPI ) act final step gastric secretion . PPI 's block ATP-ase H+/K+ gastric parietals cell . It describe inhibition acid secretion produce recovery gastroesophageal pathology high percentage patient resistant conventional drug . In context , objective study evaluate safety rabeprazole concomitant treatment examine clinical practice interaction drug whose absorption gastric pH dependence .</brief_summary>
	<brief_title>Safety Rabeprazole Patients Under Multiple Treatments</brief_title>
	<detailed_description>Rabeprazole new proton pump inhibitor ( PPI ) potent anti-secretion action dose-dependence activity . Rabeprazole rapidly eliminate hepatic metabolism renal clearance . In previous study healthy volunteer , interaction sodium rabeprazole drug warfarin , theophyline , diazepam phenytoin find . The objective study evaluate safety rabeprazole concomitant treatment examine clinical practice interaction drug whose absorption gastric pH dependence . This observational , multicenter , open prospective study . It expect enroll 500 patient receive rabeprazole concomitant drug ( one ) . All data collect prospective include follow : demographic data , adherence compliance treatment , lifestyle ( smoke alcohol consumption ) dose rabeprazole . Safety analysis base adverse event . Observational Study : For patient duodenal gastric ulcer : rabeprazole 20mg per day , orally , 4-6 week ; For patient erosive ulcerate gastroesophagic reflux : rabeprazole orally 20mg/ per day , 4-8 week ; For patient gastroesophagic reflux require prolonged treatment : rabeprazole orally 10 20 mg per day ; For patient H. Pylori : rabeprazole orally 20mg twice per day , Clarithromycin orally 500mg 2 time per day Amoxicillin 1gram orally twice daily 1 week .</detailed_description>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Stomach Ulcer</mesh_term>
	<mesh_term>Rabeprazole</mesh_term>
	<criteria>Patients receive Rabeprazole concomitant drug ( one ) nonsteroidal antiinflammatory drug ( NSAID ) , benzodiazepine corticoid Pregnant lactating patient Other severe concomitant pathology History drug alcohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Interactions</keyword>
	<keyword>Adjusted dos</keyword>
	<keyword>Duodenal Ulcer</keyword>
	<keyword>Gastric Ulcer</keyword>
	<keyword>Erosive ulcerate Gastroesophageal Reflux</keyword>
	<keyword>Rabeprazole</keyword>
	<keyword>Gastroesophageal reflux</keyword>
</DOC>